InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies. Behind nearly all diseases is a disturbance in the body’s immunological defence. If it is too active, we develop autoimmune diseases, such as diabetes or arthritis. On the other hand, weak immune responses predispose us to cancer and serious bacterial or viral infections. The development in the field has led to drugs that affect the immune system. They either strengthen the person’s own immune system or control it where it is too effective. Finnish drug development industry has introduced 22 original drugs, of which 21 have been created in Turku. Our goal is that the InFLAMES-collaboration propels the number of Finnish original drugs to new heights. In addition to developing drugs that modify the immune response in individuals, InFLAMES advances diagnostics that aim at identifying personalised treatment for each patient. This, we believe, is not accomplished alone, but in a collaboration with biotechnology and pharmaceutical companies. InFLAMES Flagship is a joint initiative of University of Turku and Åbo Akademi University, Finland. Flagship is funded by Academy of Finland.
External link for InFLAMES Research Flagship
Tykistökatu
Turku, Southwest Finland 20100, FI
Tätä kannattaa odottaa!
Olipa kerran studio, jonne astelivat Lappalainen, Laine ja Veromaa. Sen pituinen...tai siitähän vasta tarina alkaakin 😃 Pysykää kuulolla, lääkekehityksen lokikirjat avautuvat lähiaikoina! InFLAMES Research Flagship Turun yliopisto - University of Turku Åbo Akademi University
Turun yliopiston rehtori Marjo Kaartinen ja tutkimuksesta ensi vuoden alusta alkaen vararehtorina vastaava Piia Seppänen (keskellä) olivat InFLAMESin vieraana 29.10. Lippulaivaesittelyä seuranneessa monipuolisessa keskustelussa kosketeltiin muun muassa immunologian asemaa ja merkitystä lääketieteessä ja Turun yliopistoissa, innovaatiopalveluiden tärkeää roolia lippulaivassamme ja lippulaivojen jatkonäkymiä. Mukana tapaamisessa olivat InFLAMESin (vasemmalta) tutkimuspäällikkö Jarkko Koivunen, lippulaivan varajohtajat Juhani Knuuti ja Marko Salmi, johtaja Sirpa Jalkanen, tutkimuspäällikkö Joe Hettinger, projektipäällikkö Kaisa Hakkila ja tutkimuskoordinaattori Sampo Koivunen. Kiitos käynnistä Marjo Kaartinen ja Piia Seppänen! Turun yliopisto - University of Turku Åbo Akademi University Research Council of Finland | Suomen Akatemia
Vähän tiukoille menee, mutta jos tämä sattuisi kiinnostamaan, vielä ehtii hakea!
Millaista on olla Pharma Industry Future Star? ⭐ 💬 ”Ohjelma piti sisällään sopivan määrän myös kaupallisesti ja taloudellisesti mielenkiintoisia kokonaisuuksia, eikä pelkästään lääketieteellisiä osia. Ohjelma tarjosi mielenkiintoisia kohtaamisia sekä verkostoitumismahdollisuuksia toimialalle”, kertoo Laura Vasama, PIF Future Stars alumni 2024. Kiinnostuitko? Lue lisää ja hae ohjelmaan! https://lnkd.in/dbV4kqKN #lääketeollisuus #PharmaIndustry #PIFStars #PharmaIndustryFutureStars
InFLAMES Research Flagship julkaisi tämän uudelleen
Adjunct Professor of Tumor Immunology, Group Leader in the InFLAMES Flagship at Turun yliopisto - University of Turku; Chief Scientific Officer at Faron
We are looking forward to building on these findings and seeing where it takes us.
#Immunotherapy | Now here's a "Clever One" 👍 | Secreted #Clever1 impacts responses of #Tcells to limit #ImmuneCheckpointBlockade efficacy | Breaking study by Maija Hollmén & Co. | #Cancer #Therapy / #Biomarker advance 👏 | Clever–1 functions as a scavenger and adhesion receptor, promoting tolerogenic activities in macrophages and subsets of endothelial cells, thereby contributing to cancer progression. High Clever–1 expression associates with resistance to immune checkpoint inhibitors and combined targeting of Clever–1 with anti–PD–1 enhances response in refractory mouse tumor models. A Clever–1—targeting humanized IgG4 antibody, bexmarilimab, is investigated in clinical trials as a macrophage–reprogramming therapy to treat solid tumors (NCT03733990) and hematological malignancies (NCT05428969). Here*, Stuart Prince, Miro Viitala, et al* describe a secreted form of (s)Clever–1 enriched in plasma of cancer patients, that was decreased upon bexmarilimab treatment. With the production of a recombinant sClever–1, mimicking the one found in human plasma, they show that sClever–1 can selectively bind activated T cells and disrupt T cell receptor signalling leading to impaired Th1 expansion. They demonstrate that sClever–1 binds to insulin growth factor 2 receptor (IGF2R) on T cells via its mannose–6–phosphate modification and further show that sClever–1 contributes to the immunosuppressive properties of macrophage–secreted extracellular vesicles, driving T cell tolerance and impairing anti–PD–1 efficacy. These findings suggest that Clever–1 exerts a systemic immunosuppressive effect independently of the cells it is expressed on, highlighting its potential as a target in cancer immunotherapy and a valuable biomarker for disease detection. (*including contribution from Daniel Patten University of Birmingham) *https://lnkd.in/eKcfEq_3 ______________________________________________________________________________ Celentyx Ltd #immunooncology www.celentyx Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady ______________________________________________________________________________ SCHEMATIC from same group showing effect of membrane Clever-1 targeted treatment on cancer growth | Clever-1 positive M2 macrophages (pictured green) maintain cancer growth by expressing growth factors as well as immune-suppressing molecules. By blocking the action of Clever-1 with bexmarilimab (formerly known as CLEVEGEN), macrophages are converted into M1 type cells (red in the picture), expressing T-cell activating receptors and producing TNF-α (tumor necrosis factor). As a result, the tumor is targeted by a common attack of macrophages and lymphocytes and cancer cells are eliminated (tumor rejection) | https://lnkd.in/ehwBpJUm |
InFLAMES Research Flagship julkaisi tämän uudelleen
📣Planning on applying for funding in the winter call? Join our Ask & Apply webinars in October, November and December! This year we have three webinars. 🔹Tue 29 Oct at 13.00–14.00: What’s new about the winter call? 🔹Tue 5 Nov at 13.00–14.00: Call for Academy Professors 🔹Thu 12 Dec at 13.00–14.00: Ask Me anything 💡The webinars are open to everyone. 💡The webinars will be held in English. 💡The replays can be viewed later. All materials & registration links will be published online at https://lnkd.in/dpmNA_RK.
The InFLAMES Corporate Corner with the theme From Data to Innovation will be held on Thursday, 21 November 2024. The event will take place at the Cave Theatre of the Joki Visitor and Innovation Centre, Lemminkäisenkatu 12 B. We will start with lunch at 11:30, followed by the official programme until 16:00. Please join us! Registration is open. Please register by November 18 at https://lnkd.in/de5J8Qs8 Turun yliopisto - University of Turku Åbo Akademi University
Welcome to the next InFLAMES Corporate Corner! We facilitate links between university and industry,and streamline the realisation of new ideas and innovations. See you in November! Register at https://lnkd.in/de5J8Qs8.
Tämä sisältö ei ole saatavilla täällä
Käytä tätä ja paljon muuta sisältöä LinkedIn-sovelluksessa
The ImmuDocs Doctoral Education Pilot, the Turun yliopisto - University of Turku, Finland, is inviting applications for 5 fixed-term Doctoral Researcher positions at the Faculty of Medicine and Faculty of Technology from 1 January 2025 to 31 December 2027. The positions are related to the ImmuDocs Doctoral Training Education Pilot project, funded by the Ministry of Education and Culture. ImmuDocs aims to educate a new generation of experts in immunology, immunology-based drug development, and/or diagnostics. The doctoral projects open in this call for applications are as follows: 1. Exploring the Impact of Targeted Therapy on the efficacy of Immune Checkpoint Inhibitors in Metastatic Melanoma, Principal Supervisor: Carlos Rogerio Figueiredo, PhD 2. Avian influenza vaccine-induced adaptive immunity, Principal Supervisor: Ilkka Julkunen 3. Inflammatory biomarkers in neonatal hypoxic-ischemic brain injury, Principal Supervisor: Vilhelmiina Parikka 4. 3D modelling of immune component in normal and cancerous tissue, Principal Supervisor: Pekka Ruusuvuori 5. Evaluation of immune based therapies for cytomegalovirus positive cancer forms, Principal Supervisor: Cecilia Söderberg-Naucler Apply between 14 October 2024 and 28 October 2024 16:00 (Europe/Helsinki). Read more: https://bit.ly/404awfa Åbo Akademi University yEFIS International Union of Immunological Societies (IUIS) Young Scandinavian Society for Immunology
Trooppisen kuumetaudin voi nykyisin saada myös Euroopasta. Ilmaston lämpeneminen suosii trooppisten tautien ja niitä levittävien hyttysten asettumista Eurooppaan ja Amerikoihin ja niinpä hankala kuumetauti voi tulla tuliaisina matkakohteista, joissa on aiemmin voinut suhtautua melko huolettomasti hyttysten pistoihin. Mahdollisia tauteja ja taudinaiheuettajia ovat apinarokon ja lintuinfluenssan lisäksi hyttysten levittämät denguevirus, chikungunia ja zika, joka aiheutti epidemiana levitessään sikiövaurioita. Tartuntatautien ehkäisyyn on syytä varautua ja siksi EU rahoittaa rokotetutkimusta, jossa Turussa haetaan mallia lähes satavuotiaasta keltakuumerokotteesta. Erikoistutkija, InFLAMES ryhmänjohtaja Pieta Mattila perustelee Ylen Tiedeykkösen lähetyksessä, miksi keltakuumerokote on mielenkiintoinen ja lupaava kohde, kun suunnitellaan, minkälaisia rokotteita pitäisi kehittää uusien tautitulokkaiden ennaltaehkäisyyn. Ohjelmassa haastateltavana on myös zoonoosivirologian professori Olli Vapalahti Helsingin yliopistosta. Hän kertoo, mitä meidän pitäisi tietää trooppisista kuumetaudeista ja niitä levittävistä hyttysistä. #immunologia #flavivirukset #rokotteet #VektorivälitteisetTaudit #hyttyset Turun yliopisto - University of Turku Turku Bioscience Åbo Akademi University https://lnkd.in/dtRiD_dZ
Professor Sarah Teichmann from the Cambridge Stem Cell Institute and co-founder of the Human Cell Atlas was one of the keynote speakers at ECCB2024 conference held in Turku in September 2024. In her interview she explains why bioinformatics is essential in advancing research of the human cell. According to her it is essential because cell biology is driven by really high technology and large volume data both from microscopy, from genomics and from many different data types. Those data, Teichmann says, need to be processed, integrated, interpreted and then make predictions about the function of the cell. All of those activities is driven by bioinformatics. Professor Teichmann is a member of InFLAMES Scientific and Impact Advisory Board. European Conference on Computational Biology (ECCB) is an esteemed international scientific gathering held annually. This year it was organised by Turun yliopisto - University of Turku of Turku and CSC - IT Center for Science. Åbo Akademi University Laura Elo Tommi Nyrönen Sarah Teichmann FMedSci FRS Research Council of Finland | Suomen Akatemia https://lnkd.in/dFeaidwH